CKW Financial Group lowered its stake in shares of Sanofi (NYSE:SNY) by 7.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,516 shares of the company’s stock after selling 300 shares during the period. CKW Financial Group’s holdings in Sanofi were worth $168,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in SNY. Founders Financial Securities LLC purchased a new stake in Sanofi during the second quarter valued at $907,000. IFP Advisors Inc increased its stake in Sanofi by 1.9% in the second quarter. IFP Advisors Inc now owns 16,621 shares of the company’s stock valued at $796,000 after buying an additional 304 shares during the period. Eagle Ridge Investment Management purchased a new stake in Sanofi during the second quarter valued at $160,000. Stratos Wealth Partners LTD. increased its stake in Sanofi by 7.4% in the second quarter. Stratos Wealth Partners LTD. now owns 8,515 shares of the company’s stock valued at $408,000 after buying an additional 584 shares during the period. Finally, Crestwood Advisors Group LLC increased its stake in Sanofi by 1.9% in the second quarter. Crestwood Advisors Group LLC now owns 279,344 shares of the company’s stock valued at $13,286,000 after buying an additional 5,159 shares during the period. 9.96% of the stock is currently owned by institutional investors.

Sanofi (NYSE:SNY) opened at 48.08 on Monday. The stock has a 50 day moving average price of $48.11 and a 200 day moving average price of $45.82. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The company has a market capitalization of $120.75 billion, a price-to-earnings ratio of 11.54 and a beta of 0.88.

Sanofi (NYSE:SNY) last posted its earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.74. The company had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. Equities research analysts forecast that Sanofi will post $3.23 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “CKW Financial Group Sells 300 Shares of Sanofi (NYSE:SNY)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/ckw-financial-group-sells-300-shares-of-sanofi-nysesny.html.

Several equities research analysts recently weighed in on the company. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a report on Saturday. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 target price (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. Argus raised their target price on Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, June 9th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Friday, June 2nd. Finally, Berenberg Bank lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $63.75.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.